On April 4, 2022 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, reported that members of Mustang’s management team will participate in the two-day Fortress Biotech ("Fortress") Virtual R&D Summit taking place on Tuesday, April 5, 2022 and Wednesday, April 6, 2022 (Press release, Mustang Bio, APR 4, 2022, View Source [SID1234611408]). The Summit will be hosted by the B. Riley Securities’ Healthcare Equity Research team and will feature multiple programs from Fortress’ diversified pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mustang will present a corporate overview and participate in a panel discussion on Wednesday, April 6, 2022 at 1:30 p.m. ET. Registration for the event is available here.

Following the meeting, the webcast will be available on the on the News & Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days after the meeting.